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Alzheimer’s disease (AD) is a complex, multifactorial disease with a number of leading
mechanisms, including neuroinflammation, processing of amyloid precursor protein
(APP) to amyloid β peptide, tau protein hyperphosphorylation, relocalization, and
deposition. These mechanisms are propagated by obesity, the metabolic syndrome and
type-2 diabetes mellitus. Stress, sedentariness, dietary overconsumption of saturated fat
and refined sugars, and circadian derangements/disturbed sleep contribute to obesity
and relatedmetabolic diseases, but also accelerate age-related damage and senescence
that all feed the risk of developing AD too. The complex and interacting mechanisms are
not yet completely understood and will require further analysis. Instead of investigating
AD as a mono- or oligocausal disease we should address the disease by understanding
the multiple underlying mechanisms and how these interact. Future research therefore
might concentrate on integrating these by “systems biology” approaches, but also to
regard them from an evolutionary medicine point of view. The current review addresses
several of these interacting mechanisms in animal models and compares them with
clinical data giving an overview about our current knowledge and puts them into an
integrated framework.
Keywords: neuroinflammation, obesity, metabolic syndrome, type-2 diabetes mellitus, TNF, blood-brain barrier,
aging, Alzheimer’s disease
Background
Over the last century, the life span of humans living in technologically advanced societies has
expanded dramatically due to the vast knowledge gained about mechanisms underlying sustainable
health and disease, and how to implement this knowledge in the health care system. As a result,
a higher percentage of the population in these societies become centenarians as ever before, yet
certain life-style related diseases remain a problem as well. In fact, it is even questionable whether
the population as a whole is aging more healthily than before. Major obstacles to sustainable
health are metabolic diseases including obesity and diabetes mellitus (World Health Organization,
2015a,b). These diseases appear to be attracted quite easily, yet they are very difficult to treat, and
can have a devastating impact on sustainable health of individuals on the long-term (World Health
Organization, 2015a,b). It is becoming increasingly clear that diabetic and obese individuals have an
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increased risk to develop neurodegenerative diseases on the
long-term (Craft, 2005; Profenno et al., 2010). Because the
incidence of infant obesity and diabetes mellitus is on the
rise, it is expected that brain derangements like Alzheimer’s
disease (AD) will increase in the future too. AD prevalence is
estimated to reach 106.2 million people worldwide in the year
2050 (Brookmeyer et al., 2007). If one were able to delay the onset
of this disease with 12 months, this would yield 9.2 million less
cases of AD worldwide (Brookmeyer et al., 2007). A common
characteristic of metabolic diseases is a chronic and low-
grade activation of the inflammatory system (Gustafson, 2010;
Vykoukal and Davies, 2011). This inflammation may eventually
spread from peripheral tissue to the brain, and recent evidence
indeed suggests that neuroinflammation is an important causal
mechanism in AD (Hanzel et al., 2014). The current review aims
at providing an integrative neurobiological framework of the
processes that culminate from behavioral, metabolic, endocrine,
and energy balance derangements into neuroinflammation and
neurodegeneration.
Inflammation and Metabolic Diseases
Inflammation is a necessary and evolutionary conserved response
to harmful stimuli that can include tissue damage or various
pathogens that invade the host. The inflammatory response
includes numerous mechanisms and cell types (i.e., platelets,
neutrophils, macrophages, fibroblasts, endothelial cells, nerve
cells, and lymphocytes) interacting with each other to clear
out the causes of the injury, limiting ongoing infection and/or
compartmentalize damaged tissue, and to initiate tissue repair
aimed at restoring normal physiological function (Nathan, 2002).
Among others, Toll-like receptors (TLRs) on macrophages
are involved in pathogenic pattern recognition to generate
immunologically relevant responses (Takeuchi and Akira, 2010).
The release of the cytokine Tumor Necrosis Factor-alpha (TNFα)
is the prototypical response underlying inflammation and makes
up the acute phase reaction (Kmiec, 2001).Locally, TNFα
promotes cell death of damaged tissue through an apoptotic
caspase-dependent pathway (Rath and Aggarwal, 1999) allowing
repair of cells and tissue worth repairing (Winston et al.,
1999). However, TNFα also stimulates a cell survival pathway
through the nuclear factor kappa B (NF-κB) (Gupta et al.,
2005). Locally produced insulin-like growth hormone (IGF-1 and
IGF-II) orchestrates different biochemical events that culminate
into the restoration of functional integrity of damaged tissue
(Bitar, 2000). Systemically, Growth Hormone (GH) released
from the anterior pituitary influences this repair process too by
stimulating the production of IGF from the liver (Dunaiski and
Belford, 2002). IGF stimulates, for example, glucose uptake into
injured tissue (Rajpathak et al., 2009) thereby promoting energy
availability for tissue repair (Singh et al., 1998). Inflammatory
cytokines also stimulate the liver to secrete triglyceride-rich
lipoproteins, which can be used to fuel the host’s response to
infection, clear pathogens and bacteria, and may exert immune-
modulatory effects that help the innate immune response to
inflammation (Harris et al., 2000; Barcia and Harris, 2005).
Glucocorticoids acting through glucocorticoid receptors (GR)
efficiently suppress the micro-environmental IGF system (Bitar,
2000) and suppress cytokine induction downstream of TLRs
(Ogawa et al., 2005), presumably involving mitogen-activated
protein kinases (MAPK) activation (Bhattacharyya et al., 2007).
Finally, glucocorticoids reduce GH release (Tulipano et al., 2007)
through a hypothalamic somatostatin-dependent pathway. GR
belongs to the nuclear-receptor superfamily of transcription
factors, to which also the liver-retinoid receptor (LXR) and
peroxisome-proliferator-activated receptors (PPARs) belong, and
these have emerged as important modulators of innate immunity
through their effects on macrophage gene expression (Castrillo
and Tontonoz, 2004).
When the compensatory response (inflammation) is not
able to repair the damaged tissue, for example due to
chronically increased GR activation, this will turn into a
chronic condition, with continuously heightened levels of
triglycerides and cholesterol, which can lead to the formation of
atherosclerotic lesions (Esteve et al., 2005). Conditions that could
easily underlie these types of inflammations are commonly found
in obesity, and this may increase the risk for metabolic disease
like type-2 diabetes mellitus (Dandona et al., 2004; Vykoukal and
Davies, 2011; Grant and Dixit, 2015).
Metabolic Diseases
Although obesity is simply the consequence of energy intake
exceeding energy expenditure, the underlying mechanisms are
multifactorial. First of all, energy intake and expenditure are
linked with body fat as a regulated factor. This adipocentric
hypothesis–originally coined by Kennedy in the 50s of the
previous century (Kennedy, 1953)–is now well-established and
was reinforced by the discovery of the adipocyte hormone
leptin by Zhang et al. (1994). Brainstem and hypothalamic
neuropeptidergic neurocircuitry down-stream from, among
others, leptin, are involved in the homeostatic control of food
intake and energy balance, and alterations in these pathways
most often lead to secondary leptin resistance (Schwartz et al.,
2000), and often underlie weight gain (Gao and Horvath,
2008; Zeltser et al., 2012). On top of this homeostatic control
mechanism is the mesolimbic neurocircuitry involved in hedonic
aspects of food (Berridge, 2009; Berthoud, 2011). These reward
pathways can also be inhibited by leptin, thereby dampening
food-associated reward (Farooqi et al., 2007; Davis et al., 2010).
There are several other ways that affect the trajectory over which
obesity establishes itself (McAllister et al., 2009), however an
increase in the accessibility of highly palatable food items with
a highly saturated fat content and refined sugars is a leading
cause of weight gain in obesity-prone individuals, as such a
diet easily overrides homeostatic control mechanisms of energy
balance (Berthoud, 2011). At this point, it is important to
realize that these mechanisms have been shaped by evolutionary
processes, favoring genes and traits for ingestive behavior and
weight gain in times of plenty allowing survival in time of
famine (Dallman et al., 1993; Chakravarthy and Booth, 2004).
In modern industrialized societies famine is obviously not an
issue anymore, yet these genes dealing with it are probably rooted
deep in our genetic architecture (Chakravarthy and Booth, 2004),
although other theories also exist (Speakman, 2006). For these
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reasons, achieving successful weight loss is currently extremely
difficult. Eating highly palatable food can easily become addictive,
and abstinence from such food items can activate withdrawal
mechanisms (Avena, 2007; Hoebel et al., 2009). Temporary
reductions in energy intake leading to weight loss can trigger
sustainable reductions in energy expenditure that oppose further
weight loss (Rosenbaum and Leibel, 2014), and these changes
can persist long after relapse toward derailed eating behavior of
palatable and usually energy-dense food.
At some point in the progression of weight gain, adipose tissue
attracts monocytes and macrophages and changes its endocrine
functioning (Permana et al., 2006). While the exact mechanisms
are still subject of intense research (Ye, 2009; Goossens and Blaak,
2012), it is known that adipocyte/macrophage interactions lead
to production of cytokines and induce local as well as systemic
inflammatory mechanisms (Fain, 2006;Wood et al., 2009). TNFα
is known to be elevated in obese individuals, particular in those
with visceral adiposity (Tsigos et al., 1999). TNFα causes insulin
resistance by direct inhibition of insulin receptor tyrosine kinase
activity (Hotamisligil et al., 1995). In addition, IgG antibodies
linked to adipose B cell accumulation may play a role in the
development of insulin resistance in target tissue as well, since
this is attenuated by B cell depletion and conversely augmented in
lean mice that underwent IgG transfer from diet-induced obese
mice (Winer et al., 2011).
TNFα induces the secretion of other proinflammatory
cytokines, such as interleukin (IL)1β and IL6, and reduces the
secretion of the adipokine adiponectin (Wang and Trayhurn,
2006). Adiponectin increases fat oxidation in peripheral
tissue, and promotes mitochondrial biogenesis, and reduces
inflammatory markers (Yamauchi et al., 2003; Greenberg
and Obin, 2006; Lionetti et al., 2009). A reduction in plasma
adiponectin levels, at least of its high molecular weight form, has
been associated with the development of metabolic syndrome
and type-2 diabetes mellitus irrespective of changes in adipose
tissue mass (Yamauchi et al., 2001; Hojlund et al., 2006). A
comparable inhibitory effect of TNFα on the anti-inflammatory
and extracellular matrix stimulator Transforming Growth Factor
[TGF]-β has been observed (Yamane et al., 2003). The anti-
inflammatory factor IL10 conversely inhibits the TNFα system
by inhibiting TNFα converting enzyme (TACE) in monocytes
(Brennan et al., 2008) and IL10 reduces the TNFα-induced
NF-κB pathway activation as well as the apoptotic mechanisms
(Dhingra et al., 2009). Although IL10 receptors seem a promising
target for treatment of metabolic/inflammatory diseases,
however conflicting results have been found in which IL10 in
fact accelerates pancreatic Beta-cell failure (Balasa et al., 2000).
TNFα promotes spill-over of fatty acids from visceral adipose
tissue toward the liver, which contributes to elevated hepatic
triglyceride (TG) production and reduced Very Low Density
Lipoprotein clearance (Feingold et al., 1990). Consistent with this
is the finding that TNFα gene knockout mice have increased
visceral fat deposition, but have far lower hepatic fat storage
than wild-type mice (Salles et al., 2012). While the classical lipid
changes associated with the metabolic syndrome (i.e., increased
triglycerides and lipoproteins) may be envisioned as a highly
conserved evolutionary response aimed at tissue repair (Esteve
et al., 2005), these metabolic and inflammatory mechanisms can
become maladaptive and underlie the etiology of cardiovascular
and metabolic diseases (Popa et al., 2007).
Central Nervous Control of Substrate
Homeostasis
In the progression from weight gain to inflammation the
autonomic nervous system appears to play a major role. Obesity
is frequently associated with a decline in parasympathetic
activity and (regionally) increased sympathetic activity (Arrone
et al., 1997; Vaz et al., 1997; Grassi et al., 2005; Skrapari
et al., 2007; de Jonge et al., 2010). Increased sympathetic
activity is already observed before obesity establishes itself, since
diet-induced obesity prone rats can be characterized before
access to a palatable high fat diet by the hyper-responsiveness
of the sympathetic nervous system (Levin, 1993). Increased
sympathetic activity and increased blood flow through adipose
depots causes the release of fatty acids which either can be used
for metabolic purposes, or can be re-esterified in fat but also in
extra-adipose tissues including the liver and muscle (Bjorntorp,
1991). Free fatty acid (FFA) spill-over from visceral fat into the
portal circulation is caused by increased sympathetic activity in
the visceral abdominal depots, and this can easily become a self-
perpetuating process because increased FFA levels, particularly
short-chain, can activate the sympathetic limb of the autonomic
nervous system as well as the hypothalamo-pituitary-adrenal
(HPA) axis (Benthem et al., 2000). A diet with a high level
of saturated or mono-unsaturated dietary fat contributes far
stronger to abdominal weight than a diet with a poly-unsaturated
fatty acid (PUFA) content (Jang et al., 2003). Eventually, this
redistribution of fat from adipose to extra-adipose stores can
worsen insulin resistance and lead to gradual organ failure
(Unger and Scherer, 2010), provided that food intake is not
obstructed (Unger and Scherer, 2010). Whether local intra-
abdominal secretion of pro-inflammatory cytokines is increase
as a consequence of sympathetic outflow in obesity needs to
be established. This possibility may be plausible since TNFα
secretion in visceral adipose tissue is increased by sympathetic
activity induced by ischemic stroke (Wang et al., 2011). Reduced
parasympathetic activity, perhaps as a result of a shift in the
autonomic balance, is an unfavorable condition as well since
the efferent vagus nerve by means of cholinergic stimulation–
is necessary to balance cytokine production from macrophages
(Tracey, 2007).
Brain mechanisms underlying changes in autonomic outflow
in obese subjects are yet to be discovered, however the
hypothalamus may be playing a major role since it contains
preganglionic motor circuits that regulate autonomic outflow
(Luiten et al., 1985). These systems are sensitive to peripheral
hormones including insulin and leptin and can regulate
peripheral fuel fluxes (Marino et al., 2011). In addition,
enhanced afferent reflex mechanisms from adipose tissue to
the hypothalamus in obesity prone animals may contribute to
increase sympathetic activity as well (Xiong et al., 2012). Because
parts of the hypothalamus have a relatively leaky blood brain
barrier (BBB) epithelium, it is no surprise that activatedmicroglia
(i.e., which are the innate immune cells in the CNS) and increased
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levels of IgG (Yi et al., 2012) are found in the arcuate nucleus
(ARC) of the hypothalamus of mice subjected to a high fat diet
(Thaler et al., 2012; Yi et al., 2012). Analogous to the periphery,
the innate immune cells (microglia in the case of the CNS)
are important for maintaining organ physiology and relieving
cytotoxicity by clearing cell debris by phagocytotic mechanisms
(Neumann et al., 2009). In this respect the increased levels
of leptin and insulin, and several other peripheral hormones
found to be elevated in obese individuals, have neuroprotective
properties in the CNS (Signore et al., 2008). Also analogous to the
periphery is the increased secretion in the CNS of inflammatory
cytokines including TNFα as a result of feeding a high fat diet
and/or the resultant diet-induced obesity (Thaler et al., 2012).
It seems likely that increased TNFα expression in astrocytes is
more relevant for cerebral pathology than TNFα expressed in
neurons (Akassoglou et al., 1997). Increased TNFα can underlie
hypothalamic insulin and leptin resistance through the protein
tyrosine phosphatase—PTP1B pathway, which dephosphorylates
the insulin and leptin receptor associated Janus kinase (Picardi
et al., 2010). Hypothalamic insulin and leptin resistance in turn
contribute to derangements in ingestive behavior, autonomic
outflow and fuel fluxes, and eventually will augment the
inflammatory andmetabolic processesmentioned in the previous
section that fuel the vicious cycle underlying the cardio-metabolic
syndrome (De Souza et al., 2005; Posey et al., 2009; Thaler and
Schwartz, 2010; Lumeng and Saltiel, 2011).
Blood Brain Barrier Integrity
Hormonal factors like insulin and leptin not only gain access to
the hypothalamus (or other “leaky” regions like the area postrema
and subfornical organ), but virtually all brain circuits are reached
via receptor mediated transport located in the epithelium of the
BBB (Banks et al., 1996). Because plasma leptin levels increase
with higher levels of body fat (Considine et al., 1996), the level
of leptin penetrating the brain would be expected to increase as
well. This, however, is not the case since the transport system
becomes impaired by circulating triglycerides associated with
obesity and insulin resistance (Banks et al., 2004). Such a fat-
induced blockade of leptin transport across the BBB seems
maladaptive from an obesity-point of view (which in fact would
be worsened by this mechanism). Starvation, however, is also
characterized by hyperlipidemia, at least in the blood stream
(Banks et al., 2004), and the ability of triglycerides to induce
leptin resistance during famine counter the leptin-induced shift
toward use of triglycerides as an energy source and so helps
to conserve fat stores. With respect to insulin, obesity is also
associated with reduced transport across the BBB (Baskin et al.,
1985; Kaiyala et al., 2000), but this is not blocked but rather
reversed by triglycerides (Urayama and Banks, 2008). Thus, in
the case of obesity and insulin resistance, the levels of insulin
penetrating the brain can be increased, provided high levels of
circulating triglycerides.
Although the brain has a very high concentration of lipids, it
is not necessarily dependent on fatty acid oxidation as a source of
energy. Glucose is the most important energy-yielding substrate
in the CNS, which is brought across the BBB endothelium
predominantly byGLUT 1 andGLUT 3 transporters independent
of insulin (Seaquist et al., 2001). Neurons then take up glucose
directly (Patel et al., 2014), although a glucose-lactate shuttle
has also been proposed in which astrocyte nourish neurons by
lactate converted from glucose (Magistretti and Pellerin, 1999).
Glucose transport in the cortex, cerebellum, hippocampus, and
certain regions in the hypothalamus is dependent upon insulin,
via GLUT4 and GLUT8. As with the hypothalamus, insulin
resistance in these brain regions may be proposed to contribute
to hepatic insulin resistance leading to glucose intolerance and
hyperinsulinemia. As such, peripheral insulin resistance would
be adaptive in order to counter-regulate diminished glucose
availability for neuronal processes (McEwen and Reagan, 2004;
Winocur et al., 2005). Consistent with this is the idea that glucose
utilization is impaired in extremely obese Zucker compared
to lean Zucker rats (Doyle et al., 1993). The Zucker rat is a
widely used rat model for type 2 DM and is known to have
impairments in hippocampal functioning that are related to
reduction in hippocampal membrane associated GLUT4 and
insulin receptor expression (Winocur et al., 2005). In addition,
insulin dysfunctioning due to experimental (Malone et al., 2008)
or clinical (Kooistra et al., 2013; Koekkoek et al., 2014) diabetes
mellitus causes deterioration in cognitive functioning and higher
risk for stress-induced damage (Grillo et al., 2003).
Recently, Davidson and colleagues observed that hippocampal
BBB permeability of rats becomes increased (using a sodium
fluorescein penetration test) when these animals were fed a
high fat high sugar diet provided that they gained weight
(Davidson et al., 2012). Rats that did not gain weight on this
diet did not show increased leakage. The increased permeability
was found to be associated with memory impairments, in
particular hippocampus dependent learning (Davidson et al.,
2012). Obviously, a leaky BBB exposes the brain to “secondary”
risk factors that easily can do harm, and it is plausible that
this underlies the obesity-associated inflammatory process, as
was discussed previously. Monocyte/macrophage of which the
levels are found to be elevated in obesity could be transported
across the BBB and may facilitate this process, although this
idea needs to be confirmed (Freeman et al., 2014). Associations
between cognitive impairment and obesity are also found in the
human literature (Fitzpatrick et al., 2013; Vainik et al., 2013).
Causal mechanisms by which obesity affects BBB integrity are
still lacking, however it may be hypothesized that the increased
leakiness is caused by cytokines that build up over the course
of weight gain (Banks, 2005). In particular the proinflammatory
adipokine lipocalin-2 may be important as this hormone is
upregulated in obese humans and rodents (Wang et al., 2007),
and accumulation of deamidated lipocalin-2 in arteries causes
vascular inflammation and endothelial dysfunction in dietary
obese mice (Song et al., 2014). While it is quite difficult to get
cytokines in the CNS, they could affect penetration of other
compounds. Such a possibility may exist for insulin, of which
the BBB transport is increased upon lipopolysaccharide-induced
inflammation (Banks, 2005). Increased BBB transport of insulin
would make sense, because insulin resistance would counter
its earlier mentioned neuroprotective effects. BBB endothelial
cells express nuclear receptors that play a role in expression
of tight junction protein, cytokine and transporter genes (Pan
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et al., 2011). In this respect, locally released inflammatory
factors including TNFα may be a response to upregulate glucose
utilization in astrocytes, turning them into a more oxidative
state and actively contribute to increased neuronal vulnerability
(Gavillet et al., 2008). This inflammation may then in turn
causes the BBB to be weakened (Freeman et al., 2014). An
increased oxidative state would lead to increased production of
reactive oxygen species (ROS) and incur damage leading to a
decline in cognitive function (Lu et al., 2004). Recently, Freeman
et al. (2013) observed that high fat dietary-induced obese mice
had significantly higher levels of total ROS, superoxide, and
peroxynitrite in cortical regions compared to mice on a low fat
control diet. The level of oxidative stress was highly related to
the level of adiposity, and to impaired cognitive performance
(Freeman et al., 2013).
Neurodegenerative Processes
The magnitude of the above mentioned derailments clearly
predicts the risk for attracting dementia (Tolppanen et al., 2014),
even independent of genetic and early life environmental factors
(Xu et al., 2011). Thus, the collective and culminated neuronal
damage that has occurred over time will inevitably lead to signs of
dementia, as a function of age. Secondly, repair mechanisms may
become less effective with age too (O’Neill, 2013), which then also
contribute to the etiology of neurodegeneration.
GH/IGF1
As mentioned in the introduction, the GH/IGF axis plays an
important role in tissue repair and growth, and reductions in the
activity of this system with age (Ho and Hoffman, 1993) may be
relevant for age-related diseases. A reduction in GH secretion
begins after the pubertal maximum and is correlated with an
increased percentage of total body and visceral fat and decreased
physical fitness (Veldhuis et al., 1997). Bartke suggested that
the reduction in the GH/IGF axis is a necessary mechanism to
protect against cancer (Bartke, 2008). Maintenance of the activity
of the GH/IGF axis throughout life would be counter-productive
in terms of hyperfunction potentially involving the mTOR
pathway and this would increase damage rather than reducing it
(Blagosklonny, 2013). Both dietary- and age-associated increases
in adiposity are linked to a reduction in spontaneous (Vahl
et al., 1997) and stimulated (Makimura et al., 2008; Cordido
et al., 2010) GH secretion. This results in an overall reduction
in circulating levels of GH, and these too low levels may have
some repercussion for the aging process. The cause of impaired
GH secretion following dietary-induced weight gain is under
intense investigation (Steyn et al., 2013). A decreased pituitary
GH synthesis and/or release as well as an increased GH clearance
from the blood may explain the low circulating GH levels in
obese rats (Dubey et al., 1988; Ahmad et al., 1989). While caloric
excess results in lower GH levels, this is found to be associated
with higher circulating IGF-1 and insulin levels and lower insulin
sensitivity as a result of the associated weight gain (Woods et al.,
2003; Sebert et al., 2005).
There is considerable evidence that GH acts in the CNS to
affect cognitive processes. Humans that lack the GH receptor
(GH-R) show a significant loss of spatial discrimination speed
and efficiency compared to their normal relatives (Kranzler
et al., 1998). This has to some extent been confirmed in animal
studies (Li et al., 2011), although opposite effects also have been
mentioned (Banks et al., 2010). Furthermore, GH appears to be
neuroprotective against several forms of brain injuries (Hanci
et al., 1994; Winkler et al., 2000; Scheepens et al., 2001; Enhamre-
Brolin et al., 2013). A potential role for GH in development of the
CNS is supported by the widespread distribution of GH and its
receptor within the developing CNS (Garcia-Aragon et al., 1992;
Lobie et al., 1993). The effects of GH in the CNSmay be mediated
via IGF-1, analogous to the effects seen in peripheral tissue
as mentioned above. Indeed, GH or IGF1 treatment increases
hippocampal neurogenesis (Aberg et al., 2000; Aberg, 2010). IGF1
(D’Ercole, 1996; Folli et al., 1996) and IGF1R (Yan et al., 2011) are
expressed locally in diverse areas throughout the brain. Central
administration of IGF1 decreases depressive-like behavior and
brain cytokine expression, including TNFα and IL6 in mice (Park
et al., 2011).
Recently it was shown that the GH stimulatory effects
on cognitive function in rats with traumatic brain injury
is associated with increments of hippocampal and prefrontal
Brain Derived Neurotrophic Factor (BDNF) mRNA expression
and its receptor TrkB mRNA expression (Zhang et al.,
2014). BDNF is known to increase neurogenesis and neuronal
connectivity (Mattson and Magnus, 2006), and a decline in
hippocampal BDNF secretion might contribute to age-related
impairment in cognitive performance (Hattiangady et al., 2005).
Acutely elevating levels of IGF-1 in mice by microinjection
in hippocampus was found to stimulate BNDF and cognitive
performance while the opposite was observed in mice treated
with IGF-1 antiserum (Trejo et al., 2007). Neuronal transport of
BDNF, at least in isolated hippocampal tissue, has been shown to
rely on the insulin signaling cascade including phosphorylation
of PKB/Akt (Takach et al., 2015). While BDNF levels in the
CNS declines with age, diet-induced obesity lowers hippocampal
synaptic plasticity, BDNF levels and cognition (Stranahan et al.,
2008) by itself, at least in rodents. Reduced GH and IGF1 levels,
insulin resistance, as well as inflammatory markers may all
contribute to this effect (Cotman, 2005).
β-Amyloid Protein
Insulin resistance and thus increased levels of circulating insulin
have repercussions in the CNS. The breakdown of insulin in the
CNS requires insulin-degrading enzyme (IDE), a peptide that
also degrades β-amyloid protein (Aβ). Highly increased levels
of insulin therefore attenuate Aβ clearance (Ho et al., 2004).
Aβ is derived from a larger transmembrane amyloid precursor
protein (APP) (Cras et al., 1991) of which the function is not
exactly known. APP consists of a large extracellular domain, a
hydrophobic transmembrane domain, and a short cytoplasmic
carboxyl terminus. The Aβ sequence lies partially outside the
cell membrane. A heavily glycosylated region of APP lies NH2-
terminal to the Aβ sequence. This sequence is highly conserved
and is nearly identical in species from Drosophila to human
(Suh and Checler, 2002). Aβ peptides are natural products
of metabolism in their monomeric form ranging from 36 to
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43 amino acids (Querfurth and LaFerla, 2010), and probably
serve as an antimicrobial peptides (AMPs) to stimulate the
innate immune response (Soscia et al., 2010). Aβ40 is the most
common form and is much more prevalent then the aggregation-
prone Aβ42 species. Proteolysis of APP is required to obtain
these peptides, and is facilitated by sequential enzymatic actions
of beta-site APP cleaving enzyme 1 (BACE-1), a β-secretase,
and γ-secretase (Querfurth and LaFerla, 2010).While being
beneficial against bacterial infections (Soscia et al., 2010), Aβ
can form multimers or fibrils which form the core extracellular
amyloid deposits. These are surrounded and attacked by reactive
astrocytes, and reactive microglia (Cras et al., 1991; Dournaud
et al., 1995), probably as an adaptive response to confine
infectious hazards. This process, however, can induce neuronal
cell death, and will eventually result in cognitive impairment, loss
of memory functions and physical deterioration, which are all
irreversible (Belkhelfa et al., 2014). Correlated with fibrillization
are initiation of toxic and neurotoxic cascades (Dumery et al.,
2001). Aβ elicits this toxicity in its oligomeric form, and these
cytotoxic properties are mediated via a ROS pathway (Dumery
et al., 2001). Indeed this has also been confirmed in recent
research, which stated that the formation of ROS is an early
response to the oligomeric derivatives of Aβ (Giordano et al.,
2014). Other studies show that amyloid plaques are colocalized
with a variety of pro-inflammatory proteins and clusters of
reactive astrocytes and activated microglia (Eikelenboom et al.,
2010). This leads to suggest that, besides activation of the ROS
pathway, a chronic inflammatory response is activated by the
formation of Aβ-plaques, which may also underlie neuronal
cell death and impaired cognition. Indeed, Jaeger et al. showed
that mice with lipopolysaccharide-induced inflammation had
increased influx and decreased steroid-independent eﬄux of
central Aβ (Jaeger et al., 2009), which clearly would augment the
etiology of neurodegenerative processes.
Neurofibrillary Tangles
Another neurodegenerative process relates to the production of
neurofibrillary tangles (NFTs). These tangles are the result of
a misconfiguration of microtubule stabilizing protein called tau
and its associated microtubule-associated protein tau (MAPT).
NFTs are made up of paired helical filaments (PHF) (Wischik
et al., 1988; Dournaud et al., 1995), which can accumulate
within neuronal cell bodies. This can lead to de-stabilization
and eventually dissociation of microtubules. Furthermore,
intermediate aggregates of tau, like Aβ, are cytotoxic and can
impair cognition (Santacruz et al., 2005). This impairment might
be primarily caused by synaptic failure. Indeed, subjects with
mild cognitive impairment, synapses in the hippocampus begin
to decline (Querfurth and LaFerla, 2010). Furthermore, the
process of aging itself is also associated with synaptic loss,
particularly in the dentate region of the hippocampus (Querfurth
and LaFerla, 2010).As mentioned earlier, chronic inflammation,
which leads to induction of senile plaques (SPs) and NFTs, is a
key element in these neurodegenerative processes (Eikelenboom
et al., 2010). Supporting evidence for this idea comes from a study
that SPs are the source of the infection of a chronic inflammatory
response that is induced by fibrillization of Aβ, which in turn
activates an innate immune response (Eikelenboom et al., 2010).
The Aβ peptide itself is able to induce a local inflammatory
response, involving the binding of fibrillar Aβ to complement
factor C1, which then activates canonical complement pathways
in an antibody-independent fashion (Eikelenboom et al., 2006).
This activation can play an important role in the migration and
activation of microglial cells which express complement factors.
These microglial cells in turn show a high secretion level of IL6
and TNFα (Familian et al., 2006; Eikelenboom et al., 2010) in the
case of high concentration of Aβ.
In type-2 diabetic patients, the production of Aβ is
exacerbated (Sims-Robinson et al., 2010). Furthermore, studies
in mice have revealed that in both type 1 and particularly type
2 diabetes the phosphorylation of tau is increased (Kim et al.,
2009). In this case the consideration must also be made about
the fact that cognitive deficits might not only be caused by tau
phosphorylation, but also by toxicity of hyperglycemia, or by
impairment of insulin signaling per sé. Specifically, glycosylation
of O-linked β-N-acetylglucosamine (GlcNAcylation) underlies
the etiology of glucose toxicity in diabetes mellitus, and also
plays a role in neurodegenerative processes. The decreased level
of GlcNAcylation under diabetic conditions therefore suggests
an attenuating role on tau phosphorylation and tau-induced
neuronal death (Liu et al., 2009). Patients with type-1 diabetes
mellitus exhibit most problems with cognition because of a
systemic insulin deficiency. Changes in spatial learning and
hippocampal long-term potentiation (LTP) are indeed seen in
animal models of diabetes mellitus (Sims-Robinson et al., 2010).
These changes can be normalized or prevented by insulin
replacement therapy. Within the case of type-2 diabetes mellitus
cognitive impairment and neurodegeneration could be caused by
a loss of sensitivity of insulin receptors which might lead to an
increased expression of Aβ and tau (Sims-Robinson et al., 2010).
Furthermore, a decrease in insulin receptor signaling leads to
inhibition of PKB/Akt, which normally dephosphorylates (i.e.,
activates) glycogen synthase kinase 3β (GSK-3β), and that finally
leads to tau hyperphosphorylation (Sims-Robinson et al., 2010).
Activation of GSK-3β is also highly relevant to TNFα, since TNFα
can inactivate PKB/Akt via TNRF1, which leads to inactivation of
GSK-3β. Finally, down-regulation of GSK-3β leads to apoptosis
(Takada et al., 2004). Collectively, this leads to the suggestion that
there is a connection between insulin resistance and a potential
neuroinflammatory response via up-regulation of TNFα.
Balancing TNFα
Important for consideration is the fact that the binding and
signal transduction of TNFα is mediated by two TNF receptors;
i.e., TNF-Receptor 1 (TNFR1) and TNF-Receptor 2 (TNFR2)
(Zettlitz et al., 2010). TNFR1 excerpts axonal and neuronal
damage through its pro-inflammatory effects, which are clearly
observed under chronic inflammatory situations (Fischer et al.,
2011). TNFR2, however, is associated with a neuroprotective
effect against excitotoxic insults, although this has to be
confirmed in vitro (Marchetti et al., 2004). TNFR2 is considered
as an activator of the NF-κB pathway, which exerts gene
activation and anti-apoptotic signaling, but this also has a pro-
inflammatory response via TNFR1 (Kontermann et al., 2008).
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TNFR1 contains a death-domain (DD), which for that reason
can mediate apoptotic signals, while TNFR2 can mediate cell
survival and neuronal protection via the NF-κB pathway (Wajant
et al., 2003). This crosstalk is mostly mediated via the TNF-
receptor associated factor (TRAF) family, with TNFR1 activation
gene expression via indirect recruitment of TRAF1, and TNFR2
recruiting TRAF2. These factors form the basis for TNF cytokine
signaling (Inoue et al., 2000). Thus, there is a dual role of
TNFα on neuronal homeostasis, which is mediated via these two
receptors.
The finding that TNFα is not solely produced by macrophages
and other immune-regulating cells, but also by adipose tissue
in obese (and insulin-resistant) mice (Moller, 2000) and
even in human adipocytes in individuals with obesity or
hyperinsulinemia, may suggest a causal link between processes
in the brain and the periphery. Weight loss in obese individuals
correlates with a reduction of circulating TNFα levels and
other inflammatory cytokines (Bruun et al., 2003), which may
eventually lead to a reduced activity of neuroinflammatory
pathways in the brain (Ghanim et al., 2012). Thus, this evidence
collectively suggests that obesity and/or diabetes mellitus induces
a neuroinflammatory response which upregulates TNFα and
other pro-inflammatory cytokines that via multiple pathways
leads to an increased risk of neurodegeneration.
Progression toward Alzheimer’s Disease
The processes and pathways mentioned above can at some
point lead to such cognitive impairments that they become
classified as AD. Memory loss is the most presenting symptom
found in people developing AD (Burns and Iliffe, 2009). Also
present are symptoms as poor sleep quality (Landry and Liu-
Ambrose, 2014), emotional changes, anxiety and depression
(Burns and Iliffe, 2009). This cognitive deterioration furthermore
coincides with the neuropathological staging of AD (Braak and
Braak, 1991; Schroeter et al., 2009). At the age AD manifests
itself (frequently around the age of 65) (Brookmeyer et al.,
1998), the neurodegenerative processes are already ongoing for
many years, or perhaps even decades, yet its progression can
differ substantially between patients. Advancing dementia in
AD correlates strongly with the disproportional loss of synapses
between neurons (DeKosky and Scheff, 1990). The number of
NFTs is directly related to the severity of AD, and could serve as
a pathologic marker (Querfurth and LaFerla, 2010). The initial
indication that led to show the contribution of TNFα in AD
was the presence of TNFα in the vicinity of SPs in post-mortem
AD brains (McCoy and Tansey, 2008). This co-localization of
TNFα and SP was also seen in brains of transgenic mice that
expressed APP. The fact that transgenic mice with deletion of
TNFR1 show a significant decline in microglia activation, BACE1
activity, Aβ pathology, less memory deficits and less neuron loss
indeed suggest a role for TNRF1 in the pathogenesis of AD (He
et al., 2007). A potent and effective method of treating AD via
the TNF signaling pathway is therefore anticipated. Targeting the
TNF signaling pathway in neurodegenerative diseases such as AD
is a strategy, which has received increasing amounts of interest.
Human-specific reagents, which target the neurodegenerative
and neuroprotective effects of respectively TNFR1 and TNFR2
are for example ATROSAB, a human specific antagonistic TNFR1
antibody (Zettlitz et al., 2010), and Tenascin C single chain TNF
(TNC-scTNF) (Fischer et al., 2011), a TNFR2 selective agonist.
By selectively inhibiting TNFR1 and/or activating TNFR2, the
neuroprotective effects of these receptors might be of use as a
possible break on the neuroinflammatory pathway involved in
neurodegenerative processes.
Several studies have already confirmed that patients with
diabetes mellitus have an increased risk of developing AD
(Brands et al., 2005; Biessels et al., 2006). About 80% of
patients with AD exhibit symptoms of glucose intolerance or
diabetes mellitus (Janson et al., 2004). Several factors associated
with obesity including hyperglycemia, insulin resistance, glucose
intolerance, atherosclerosis, adiposity and hypertension (Haan,
2006) can increase the risk for attracting AD too. Interestingly,
being overweight or obese more strongly increases the risk
for developing AD later in life, than being overweight or
obese at late life (Emmerzaal et al., 2015). In their meta-
analysis on epidemiological studies on the link between obesity
and AD, Emmerzaal et al concluded that “current trends of
more overweight and obesity in childhood and adolescence
may translate to longer exposure of the brain to potentially
detrimental vascular and metabolic effects of adipose tissue. This
increased size of the population at risk in combination with
longer survival, continues to underscore the importance and
necessity of research in this field” (Emmerzaal et al., 2015). In the
following paragraphs, a number of factors are described which
have been mentioned to affect the risk for attracting AD.
ApoE
Early-onset familial AD (EOAD) (under 65 years of age) is
usually the cause of an age-related dichotomy of rare autosomal
dominant mutations (Bertram et al., 2007). The risk of late-
onset AD (LOAD) (over 65 years of age) is on the other hand
increased by genetic variants of which the penetrance is relatively
low, but prevalence high (Tanzi, 1999). LOAD probably accounts
for about 95% of all AD cases. The one genetic factor that has
been firmly established to underlie LOAD is the ε4 allele of
Apolipoprotein E (ApoE, ApoE-ε4). ApoE is a protein that is
mainly involved in the transport of cholesterol (Strittmatter et al.,
1993). The production of ApoE is mediated by astrocytes, which
then secretes it into the CNS in high-density lipoprotein (HDL)-
like particles. ApoE levels are upregulated following injury and
during development, so it functions mainly in growth and repair
(Strittmatter et al., 1993). An increase of ApoE is also seen in
several chronic neurodegenerative diseases, such as AD, in which
ApoE binds to SP and NFT (for review see Liu et al., 2013).
The suggestion that ApoE serves as a genetic predisposing factor
comes from the observation of high levels of ApoE mRNA in
brains of patients with AD (Strittmatter et al., 1993). Through
the action of the ATP-binding cassette transporter (ABCA1) and
other related transporters, ApoE is lipidated. ABCA1 normally
serves to transfer phospholipids and cholesterol to ApoE (Jiang
et al., 2008). Research suggests that the lipidated form of ApoE
acts to enhance the clearance of Aβ peptides from the brain, in
the form of elevated proteolytic breakdown. There are multiple
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isoforms of ApoE, of which ApoE-ε4 is one of these. The ApoE-
ε4 isoform differs structurally from other isoforms resulting in
the fact that this ApoE-ε4 protein mediates neuronal death and
neurodegeneration, and thus not have the same Aβ proteolytic
properties (Bagyinszky et al., 2014).
As opposed to LOAD, EOAD is characterized by mutations
in the APP gene, presenilin 1 (PSEN1) gene and presenilin
2 (PSEN2) gene. Mutations in these genes might result in
alteration of Aβ production (both Aβ40 and Aβ42), which can
lead to apoptosis and dementia (Bagyinszky et al., 2014). The
involvement of the APP gene has been discovered in patients with
Down syndrome who are prone to develop AD at a very early age.
Triplication of the APP gene, which is localized on chromosome
21, is the cause of this greater predisposition of early onset of AD
pathology in patients with Down syndrome (Bagyinszky et al.,
2014).
Because of the involvement of ApoE in lipid-transport and
its role in the clearance of Aβ, this is a significant risk factor
to discuss. ABCA1 expression, because of its lipidation action
of ApoE, is a crucial transporter-protein. The expression of
both ABCA1 and ApoE are induced by the Liver X receptor
(LXR), which is a ligand-activated transcription factor (Jiang
et al., 2008). LXR acts as a sensor for cholesterol and is activated
by oxysterol (oxidized derivatives of cholesterol), which results
in a rapid increase of lipidated forms of ApoE (Cao et al.,
2007; Jiang et al., 2008). This is where lifestyle factors first
come into play in the onset and progression of AD, because
it suggests a strong link between AD and dietary habits, the
cardiovascular system, and metabolism. For example, it has
been shown that high systolic blood pressure at midlife is
a significant risk for developing AD later in life (Kivipelto
et al., 2001). Furthermore, the same research also revealed a
link between high serum cholesterol concentrations as a risk
for AD. Combining these two risk factors probably contribute
in a synergistically fashion to the proneness of AD. The
mechanism behind these interactions however remains quite
complex, and clearly more research is necessary to unravel them.
It may however be speculated that a high cholesterol intake
elevates the serum cholesterol levels, which create an overload
of ApoE, which then leads to a down-regulated proteolysis
of Aβ (Puglielli et al., 2003). Susceptibility for AD increases
further in carriers of the ApoE-ε4 SNP, because of the higher
cholesterol content of the ApoE-ε4 lipoproteins. Furthermore,
in patients with AD, lecithin cholesterol acyltransferase (LCAT)
activity is significantly reduced, suggestively by the ApoE-
ε4 SNP (Puglielli et al., 2003). LCAT is an enzyme that
catalyzes the process that clears cholesterol from peripheral
cells.
TNFα may interact with ApoE, at least in atherogenic
processes in mice that were feeding a diet rich in saturated
fat and cholesterol (Ohta et al., 2005). This upregulation of
TNFα is probably involved in the inflammatory responses in
atherogenesis, mediatedmainly by its soluble form of the TNFR1.
Whether this TNFR1 mediated pathway provides the link
between a high fat/cholesterol diet and the neuroinflammatory
responses, which can promote the onset of AD remains to be
investigated.
Saturated Dietary Fat
As mentioned earlier, a diet with a high level of saturated
or mono-unsaturated dietary fat contributes far stronger to
abdominal weight than a diet with a poly-unsaturated fat
content (Jang et al., 2003). The statement that a high fat
diet may be a contributing factor in neuroinflammation is
partially established by the fact that a high fat diet has been
reported to induce a CNS inflammatory response by means
of an enhanced systemic inflammation (Timmermans et al.,
2014). Furthermore, numerous previous studies have shown
the effect of high fat feeding on microglial activation and
overall neuroinflammation in specific brain regions (Thaler and
Schwartz, 2010; Fuente-Martin et al., 2012; Thaler et al., 2012). In
accordance, considering the risk factors age and obesity, which
are both associated with neuroinflammation (Labrousse et al.,
2012; Makki et al., 2013), also seem to both have a lowering on
overall testosterone levels inmales (Teerds et al., 2011; Jayaraman
et al., 2014) which then in turn also affects neuroinflammation
in rodents (Jayaraman et al., 2014). Particularly high levels of
saturated fatty acids (SFA) may increase the risk of dementia and
even AD later in life (Kalmijn et al., 1997; Morris et al., 2004;
Eskelinen et al., 2008), suggestively via mechanisms involving
ApoE-e4 (Laitinen et al., 2006) and may also be conveyed by
inflammatory mechanisms (James et al., 2000). The same study
suggests the counteracting effect of omega-3 poly-unsaturated
fatty acid (n3-PUFA) ingestion on systemic inflammatory
cytokines such as TNFα (James et al., 2000). Recent studies
concur with this suggestion, showing that specific n3-PUFAs
exert profound anti-inflammatory effects on the brain after
neuroinflammatory challenges (Bazan, 2007; Belayev et al., 2009;
Orr et al., 2013; Zendedel et al., 2015). Particularly decreased
levels of the n3-PUFA docosahexaenoic acid (DHA) correlate
with cognitive impairment and are established to be decreased
in AD (Prasad et al., 1998; Suzuki et al., 1998; Bazan, 2007; Orr
et al., 2013). It is suggested that Western diets do not provide the
aged brain with an optimal supply of these n-3 PUFAs (Woo,
2011; Cutuli et al., 2014). Even more convincing are the facts
that the aged brain shows a reduced capacity of n-3 PUFAs to
pass the BBB and to convert shorter chained fatty acids to longer
fatty acids (Yehuda, 2012; Cutuli et al., 2014). There is a possible
beneficial effect of n-3 PUFA supplementation (including DHA)
that may improve hippocampal functioning in aged mice (Cutuli
et al., 2014). Unfortunately, the aforementioned ApoE-e4 carriers
appear to be unresponsive to the protective effect of n3-PUFA
supplementation (Barberger-Gateau et al., 2011). Furthermore,
n-3 PUFA supplementation seems inefficient at old age to prevent
cognitive decline or when AD has been diagnosed already,
and should thus be regarded as preventive rather than curative
(Cederholm et al., 2013; Jiao et al., 2014)
Sedentary Lifestyle
Leading a sedentary life style is known to be a factor that
contributes to weight gain, an at a population level a reduction
in obesity and sedentary living increases the number of years
without cognitive impairment (Anstey et al., 2014). Chronic
exercise is also associated with preservation of overall cognitive
function and prevention of dementia (Zhao et al., 2014). It is
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difficult to dissociate the beneficial effects of physical activity
on cognitive function independent of its effects on peripheral
endocrine and cardiometabolic health. However, exercise is a
proven stimulus of GH release and an acute bout of exercise
stimulates a significant GH pulse (Pritzlaff et al., 2000; Wideman
et al., 2002; Godfrey et al., 2003), although the effects in
the elderly seems diminished (Marcell et al., 1999). However,
resistance training over a 12 week exercise protocol in elderly
people promoted an increase in acute GH response, possibly
owing to an increase ability to exert oneself (Craig et al.,
1989). Thus, exercise is a potent stimulator of GH and IGF1
release and it may take a few hours to recover back to baseline
levels (Kanaley, 2008). It is speculated that the mechanism
responsible for exercise-induced GH release is a suppression
of hypothalamic secretion of somatostatin and possibly during-
high intensity exercise an augmented hypothalamic secretion of
GHRH. The primary function of GH release during exercise
may be post exercise protein synthesis (Kanaley, 2008). Basal
levels of IGF-1 decrease during aging (Yamamoto et al., 1991;
Ruiz-Torres and Soares de Melo Kirzner, 2002; Trejo et al.,
2004). Trejo et al. (2002) have pointed out that physical activity
increases the uptake of IGF into CNS, and IGF may activate
the synthesis and release of nerve growth factors (NFGs). In
rodent studies, exercise is known to stimulate BDNF expression
and release in the hippocampus, in this is associated with
increased cognition and increased PKB/Akt phosphorylation
(Aguiar et al., 2011). In addition, wheel-running aged mice had
attenuated microglial proliferation and increased expression of a
proneurogenic hippocampal phenotype compared to sedentary
mice (Kohman et al., 2012). Stranahan et al. observed that
exercising mice had increased hippocampal BDNF levels and
associated increased spine density (i.e., compared to sedentary
mice), and this effect was also observed in genetically obese mice,
yet less outspoken (Stranahan et al., 2008). Interestingly, elevating
hippocampal BDNF signaling by the TrkB receptor increases
“browning” of white adipose tissue and adaptive thermogenesis
(Cao et al., 2011), which would constitute a positive feedback, and
may explain the positive effects of physical activity on metabolic
as well as cognitive health.
Finally, long-term exercise treatment reduces oxidative stress
in the hippocampus of aging rats (Marosi et al., 2012).
Furthermore, it has also been shown in a mouse model
that exercise can attenuate the DNA binding of NF-κB,
which essentially suggests a decrease in inflammation, possibly
involving TNFα. Healthy volunteers who received an injection
with a low dose of Escherichia coli endotoxin showed a two- to
threefold increase of circulating TNFα, and this was significantly
reduced by exercise (Petersen and Pedersen, 2005). Because
ROS and inflammatory cytokines were discussed earlier to be
involved in an early response to the oligomeric derivatives
of Aβ, exercise would therefore slow progression of AD.
Exercise can also increase vagal tone, which suggestively reduces
the inflammatory response because of the aforementioned
cholinergic anti-inflammatory response (Woods et al., 2012). In
summary, exercise affects multiple organ and organ systems,
which contribute via different mechanism to delay the onset and
progression of AD.
Stress
It was mentioned earlier that obesity is associated with an
increase in sympathetic activity (Arrone et al., 1997; Skrapari
et al., 2007; de Jonge et al., 2010) and HPA axis activity
(Bjorntorp, 1991; Benthem et al., 2000), which both could
result from a reflex mechanisms involving fatty acid spill-over
from abdominal fat depots toward the liver. Psychological or
psychosocial stress also lead to enhancement of sympathetic
activity and HPA axis activity, which are required to fuel a
fight/flight response (Koolhaas et al., 2011). In our society of
plenty, however, fight/flight responses are no solution for our
stressors to which we are exposed. Furthermore, living in a
complex society can impose stressors that are chronic in nature.
As a result, stress responses become extended, and without the
physical component of stress would incur damage (McEwen and
Wingfield, 2003), with the higher spill-over of fat and glucose
propagating sympathetic and HPA axis activity. Eating highly
palatable food items can be rewarding and may be protective
against deterioration of mood (Dallman, 2010), but would not
fuel physical activity, and thus would enhance cardiometabolic
damage. Reader et al used a repeated social defeat (RSD) stress
model for induction of chronic psychological/psychosocial stress
and observed increased microglial activation, which is a proxy
for neuroinflammation (Reader et al., 2015). In a psychosocial
stress model, submissive animals develop depressive-like
behavior (Norman et al., 2010), which is often associated with
an increased inflammatory state (Cohen et al., 2012). The
mechanistic links between inflammation and depression are
well understood (Norman et al., 2010; Capuron and Miller,
2011; Reader et al., 2015), and may involve HPA axis activity
and sympathetic activity (Reader et al., 2015). A permissive
action of the endothelial IL1 receptor and stress-induced
neuroinflammation and anxiety-like behavior was recently
established (Wohleb et al., 2014a), and monocyte trafficking
across the BBB probably plays an important role in this link
(Wohleb et al., 2014b).
Increasing parasympathetic activity might have beneficial
effects on inflammation, as reviewed by Tracey (2007). As already
mention, Tracey exposed the effects of stimulating the vagus
nerve and administrating nicotine which inhibits TNFα release
and various other pro-inflammatory cytokines (Borovikova et al.,
2000; Wang et al., 2003; Tracey, 2007; Pavlov and Tracey,
2012). Increasing parasympathetic activity would also normalize
autonomic disbalance in the obese state, in which sympathetic
activity is known to be increased (Arrone et al., 1997; Vaz et al.,
1997; Grassi et al., 2005; Skrapari et al., 2007; de Jonge et al.,
2010). Thus, by increasing parasympathetic tone, the vicious
cycle including increased fatty acid spill-over and increased
sympathetic and HPA activity would be broken. Indeed, vagal
nerve stimulation (VNS) has been used in the treatment of
AD. Vonck et al. (2014) recently gave an overview of the
studies addressing VNS, and alluded to the idea that anti-
inflammatory pathways in the CNS are set in motion by VNS
that are beneficial for AD patients. Whether this would also
work under conditions of psychosocial or psychological stress is,
to our knowledge, unclear. Because stress augments Aβ release
and amyloid aggregation in animal models of AD (Dong and
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Csernansky, 2009; Srivareerat et al., 2009) further research in this
field is therefore warranted.
Circadian Disorders
Finally, the role of circadian dysregulation as a considerable
risk factor for neuroinflammatory responses deserves some
attention, as it will increase the risk of neurodegenerative
diseases. Circadian disorders are primarily caused by deficits
in the circadian system driving the 24 h rhythms in body and
brain. In the brain, the hypothalamic suprachiasmatic nucleus
(SCN) has been identified as the master circadian clock driving
many other circadian clocks and clock systems. One important
function of this clock is the regulation of the sleep/wake
cycle. Disruptions of the circadian clock will lead to sleep
disturbances, and these sleep disturbances (e.g., sleep loss) in
turn cause a neuroinflammatory response (Wisor et al., 2011).
As such, circadian disorders can be viewed as a distinctive
pro-inflammatory factor. It has been recently recognized that
improvements in circadian rhythm functioning as well as
appropriate sleep interventions should therefore be further
explored in order to delay neurodegenerative progression, and
notably so in case of AD (Landry and Liu-Ambrose, 2014). The
age-related alterations in innate immunity and chronic systemic
inflammation cause a persistent neuroinflammatory state. This
state accelerates degenerative diseases via its dysregulation
of clearance mechanisms of misfolded or damaged neuronal
proteins and loss of axonal integrity linked to tau-pathology
(Krstic and Knuesel, 2013). In a study comparing the SCN
of young and aged mice, it was found that neurons and glial
cells of the SCN are sensitive to inflammatory signals (Sadki
et al., 2007). The response of the aged glial cells in the SCN is
markedly more pronounced to cytokine exposure (Bentivoglio
et al., 2006). In the aged SCN, it is notably the circadian output
toward other hypothalamic nuclei that is disrupted (Van der Zee
et al., 1999; Weinert, 2000). A successful intervention would
be the one, which improves circadian output pathways. One
such intervention could be exercise, as it has been shown to
strengthen the circadian system in aged mice (Leise et al., 2013).
The cholinergic system provides input to the circadian clock,
and it has been hypothesized that reduced cholinergic input
FIGURE 1 | Detrimental and healthy life style factors respectively
stimulate and reduce the risk for attracting obesity, the metabolic
syndrome and type-2 diabetes mellitus. These factors also have a
stimulatory effect per sé on age-related damage and accelerate senescence.
Associated with obesity, metabolic syndrome, and type-2 diabetes mellitus,
there is inflammation, insulin resistance, and hyperinsulinemia (i.e., depending
on the stage of type-2 diabetes mellitus). Hyperactivity of the sympathetic
nervous system and HPA axis worsen insulin resistance and deteriorate
cardiovascular health. At the level of the brain, several mechanisms are set in
place, among which neuroinflammation and insufficient brain fueling are
proposed to backfire and contribute to increased sympathetic and HPA
activity as well. Finally, these processes lead up to Aβ aggregation, Tau
hyperphosphorylation, and NeuroFibrillary Tangle (NFT) deposition, which
also backfire and culminate into AD. (1) Upregulating ketone provision to the
brain, (2) exercise/physical activity, and (3) increasing the level of n-3 PUFAs
(by diet supplementation as preventive action) slow the progressive stages in
the disease, and are also proposed to reduce the backfiring effects, which
puts a brake on the vicious cycles in the etiology of AD.
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hampers several circadian clock-dependent processes, including
sleep as well as learning and memory (Hut and Van der Zee,
2011; Mulder et al., 2013). As acetylcholine release inhibits
the production of proinflammatory cytokines by microglia
(Shytle et al., 2004), the cholinergic system has been suggested
to function as a mediator in neuroinflammatory responses.
However, neuroinflammation has been shown to selectively
disrupt the cholinergic system (Araujo et al., 1989). Hence,
increasing levels of neuroinflammation impair the cholinergic
system and reduce its inhibitory role on proinflammatory
cytokine production, further worsening the situation. Taken
together, the aging SCN is at increasing risk of becoming
damaged by (excessive) neuroinflammation. This will lead to
(further) circadian dysregulation, and as a result increased
disturbance of the sleep/wake cycle and hence increasing
excessive neuroinflammatory responses even further. Obesity
is known to be associated with circadian (Roenneberg et al.,
2012) and sleep (Kudlow et al., 2013) derangements, and
circadian disturbances inflate the metabolic syndrome (Staels,
2006). Improving the function of the SCN and maintaining
the expression of circadian rhythmicity should therefore
be one of the critical interventions toward slowing down
neurodegeneration caused by neuroinflammatory processes.
Concluding Remarks
Neuroinflammation, processing of APP to the Aβ peptide, tau
protein hyperphosphorylation, relocalization and deposition, are
the leading mechanisms in AD. These processes are propagated
by obesity, the metabolic syndrome and type-2 diabetes mellitus.
Stress, sedentariness, dietary overconsumption of saturated fat
and refined sugar, and circadian derangements/disturbed sleep
all contribute to obesity and related metabolic diseases, but also
accelerate age-related damage and senescence that all feed the
risk of developing AD. It is difficult to make clear separations
between these mechanisms, as they are strongly overlapping and
integrated.
The choice for addressing above-mentioned issues in relation
to the TNF system was provided by its major role in immune
regulation with widespread implications. TNFα is however not
the least complex in this case. Although many mechanisms have
beenmentioned with respect to TNFα, these are probably the “tip
of the iceberg.” This is for example illustrated by the complex
crosstalk that exists between the two TNF-receptors: TNFR1 and
TNFR2. TNFR1 translates mainly proinflammatory signals, while
TNFR2 is thought to primarily be a pro-survival signal (Naude
et al., 2011). Because of the diversity of functions of TNFα, which
is not restricted to either TNFR1 or TNFR2, it becomes very
complex and can be dependent on the temporal dynamics of this
crosstalk and under the given (patho) physiological condition in
which they take place.
As to why AD develops, we speculate that this is initially
an adaptive response of the brain that becomes maladaptive.
Inflammation in the brain, analogous to inflammation in
peripheral organs and tissues, is a response to damage and
requires fuels for restorative actions. Migration of macrophages
and monocytes across the BBB and glial activation are highly
adaptive in this sense too. Weakening of the BBB endothelium in
the obese state allows this migration to occur. The brain requires
glucose for metabolic purposes, however insulin resistance in
certain brain regions makes this a problematic event. The
deficient energy status implicated in the neurodegenerative
pathology has previously been coined “type-3 diabetes mellitus”
(Steen et al., 2005). Thus, a coordinated response of a
chronically injured brain (which we believe occurs with obesity
and particularly with metabolic diseases like type-2 diabetes
mellitus) would be to increase fuel availability by (1) activating
sympathetic nervous system outflow and HPA axis activity,
and (2) promote food consumption. Increased basal and cold-
induced sympathetic and HPA axis activity have indeed been
demonstrated in AD patients (Pascualy et al., 2000). In the
case of obesity and metabolic derangements, these responses
would obviously worsen the etiology of the disease. Besides
glucose, the brain can also utilize ketones for metabolic purposes
(Owen et al., 1967). Ketone bodies are elevated in conditions
of food restriction, and both food restriction as well as ketone
body supplementation are neuroprotective, but hypoglycaemia
(another feature of food restriction) is not neuroprotective
(Davis et al., 2008). Feeding a diet very low in carbohydrates
and usually rich in proteins and fat is also ketogenic, and has
been shown to slow the progression of AD too (Gasior et al.,
2006). The neuroprotective effects may result from enhancing
energy provision by ketones to resist or fight metabolic and
inflammatory challenges (Julio-Amilpas et al., 2015).We propose
here that the brain misinterprets “obesity” for “starvation.”
Thus, both obesity and starvation are characterized –among
others–by shutting down leptin access toward the brain, insulin
resistance, and hypertriglyceridemia, but the compound to
fuel neuronal metabolic processes for repair (i.e., ketones)
is lacking in obesity. For this reason obesity and associated
metabolic disease may underlie an energy crisis in the brain
that leads to an insufficient counteraction of accumulating
damage and finally will increase the risk to develop AD
(see Figure 1).
Sustainable health is important for one’s physical and mental
well-being, social presence and quality of life, apart from the
absence of disease (World Health Organization, 2015a,b), but
this is in first place achieved by making healthy and conscious
lifestyle decisions in which ample exercise and sleep, healthy
dietary habits, and a manageable mental stress level are defining
factors. Eventually, these choices can be traced to a molecular
level and very specifically translated into how and where these
have an action on, but also were they can go awry and eventually
develop into disease. Once a disease -like AD- has developed,
the underlying mechanisms are often obscured. Only studying
the adaptive and maladaptive processes from the earliest possible
stage onwards at the highest level of molecular and temporal
resolution without forgetting the bigger picture in both humans
as well as animal models will eventually unravel the exact
underpinnings of AD.
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